{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:43:24Z","timestamp":1789177404316,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Vigonvita Life Sciences Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Simenafil, a potent and highly selective oral phosphodiesterase type 5 (PDE5) inhibitor, is currently under investigation for erectile dysfunction (ED) treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of simenafil for ED treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 3 study in men aged 18-75\u00a0years with a history of ED of 6\u00a0months or more. The subjects were randomized in a ratio of 1:1:1:1 to on-demand receive fixed-dose either placebo or simenafil (2.5\u00a0mg, 5\u00a0mg or 10\u00a0mg) for 12\u00a0weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Primary efficacy endpoints were the least square mean (LSM) changes from baseline to week 12 in the erectile function (EF) domain of the International Index of Erectile Function (IIEF), percentages of \u201cyes\u201d responses to sexual encounter profile (SEP) diary question 2 (SEP Q2: Were you able to insert your penis into your partner\u2019s vagina?) and question 3 (SEP Q3: Did your erection last long enough for you to have successful intercourse?)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 765 patients were randomized and 92.3% completed the study. The mean age of subjects was 41.3\u00a0years and 81.6% had moderate to severe ED (mean overall International Index of Erectile Function\u2013Erectile Function (IIEF-EF) domain score 13.4). After 12\u00a0weeks of treatment, doses of 2.5, 5, and 10\u00a0mg of simenafil exhibited substantial increases than placebo in IIEF-EF score (12.3, 12.3, 12.7 vs. 9.6), the percentages of \u201cyes\u201d responses to SEP Q2 (40.58%, 42.43%, 43.98% vs. 32.05%), and SEP Q3 (61.91%, 63.70%, 65.19% vs. 46.70%) (all P\u2009&amp;lt;\u2009.001). Adverse drug reactions (ADRs) occurred in 36.2% of patients who received simenafil (32.6% in simenafil 5\u00a0mg group, the clinically recommended dose) and in 30.9% of those who received placebo. The most common (\u22652%) ADRs were dizziness, headache, flushing, nasal congestion, and dry mouth, and most were mild or moderate. Furthermore, abnormal vision (PDE6 related) and myalgia (PDE11 related) did not occur in patients who received simenafil.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Simenafil is highly effective in all 3 dose groups and has a low effective dose and good safety profile, providing a novel, favorable treatment option for patients with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>The efficacy and safety evaluation of simenafil in difficult-to-treat patients with ED, ED patients with other concomitant diseases, and other ethnic populations was not performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Simenafil is an effective and well-tolerated therapy for patients with ED.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf109","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:40:46Z","timestamp":1751935246000},"page":"1430-1439","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial"],"prefix":"10.1093","volume":"22","author":[{"given":"Yuzhuo","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University First Hospital , Beijing , 100034,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Anhui Medical University , Hefei , 230022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Andrology and Sexual Medicine, Institute of Sexual Medicine, the Second Hospital of Dalian Medical University , Dalian , 116023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital , Haidian District, Beijing , 100191,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Andrology, the First Bethune Hospital of Jilin University , Changchun , 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Andrology, Nanchang Reproductive Hospital , Nanchang , 330004,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Andrology, Guangzhou First People's Hospital , Guangzhou , 510180,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Andrology, Henan Provincial People's Hospital , Zhengzhou , 450003,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Chengdu University , Chengdu , 610081,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Urinary Surgery, Peking Union Medical College Hospital , Beijing , 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Urology, the Affiliated Hospital of Changchun University of Chinese Medicine , Changchun , 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Andrology, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing , 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai , 201203,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Juan","sequence":"additional","affiliation":[{"name":"Vigonvita Life Sciences Co., Ltd. , Suzhou , 215123,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Duan","sequence":"additional","affiliation":[{"name":"Vigonvita Life Sciences Co., Ltd. , Suzhou , 215123,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital , Beijing , 100034,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"24","key":"2025080406265937600_ref1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1056\/NEJM200006153422407","article-title":"Erectile dysfunction","volume":"342","author":"Lue","year":"2000","journal-title":"N Engl J Med"},{"issue":"9861","key":"2025080406265937600_ref2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0140-6736(12)60520-0","article-title":"Erectile dysfunction","volume":"381","author":"Shamloul","year":"2013","journal-title":"Lancet"},{"key":"2025080406265937600_ref3","doi-asserted-by":"publisher","first-page":"16003","DOI":"10.1038\/nrdp.2016.3","article-title":"Erectile dysfunction","volume":"2","author":"Yafi","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2025080406265937600_ref4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jsxm.2017.08.009","article-title":"Prevalence and risk factors for erectile dysfunction in Chinese adult males","volume":"14","author":"Zhang","year":"2017","journal-title":"J Sex Med"},{"issue":"4","key":"2025080406265937600_ref5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jsxm.2019.01.314","article-title":"Erectile dysfunction: an umbrella review of meta-analyses of risk-factors, treatment, and prevalence outcomes","volume":"16","author":"Allen","year":"2019","journal-title":"J Sex Med"},{"issue":"4","key":"2025080406265937600_ref6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ucl.2021.06.009","article-title":"Physiology of erection and pathophysiology of erectile dysfunction","volume":"48","author":"MacDonald","year":"2021","journal-title":"Urol Clin North Am"},{"issue":"4","key":"2025080406265937600_ref7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ucl.2005.08.007","article-title":"Physiology of penile erection and pathophysiology of erectile dysfunction","volume":"32","author":"Dean","year":"2005","journal-title":"Urol Clin North Am"},{"issue":"2","key":"2025080406265937600_ref8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5534\/wjmh.2013.31.2.83","article-title":"Korean Society for Sexual Medicine and Andrology (KSSMA) guideline on erectile dysfunction","volume":"31","author":"Ryu","year":"2013","journal-title":"World J Mens Health"},{"issue":"3","key":"2025080406265937600_ref9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.juro.2018.05.004","article-title":"Erectile dysfunction: AUA guideline","volume":"200","author":"Burnett","year":"2018","journal-title":"J Urol"},{"issue":"8","key":"2025080406265937600_ref10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/j.1742-1241.2006.01049.x","article-title":"Comparison of phosphodiesterase type 5 (PDE5) inhibitors","volume":"60","author":"Wright","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2025080406265937600_ref11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"2025080406265937600_ref12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/14656566.6.1.75","article-title":"Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction","volume":"6","author":"Doggrell","year":"2005","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"2025080406265937600_ref13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2165\/00003495-200565120-00003","article-title":"A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?","volume":"65","author":"Hatzimouratidis","year":"2005","journal-title":"Drugs"},{"issue":"Suppl 1","key":"2025080406265937600_ref14","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int J Impot Res"},{"issue":"23","key":"2025080406265937600_ref15","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1021\/jm301159y","article-title":"Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5","volume":"55","author":"Wang","year":"2012","journal-title":"J Med Chem"},{"issue":"10","key":"2025080406265937600_ref16","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1021\/acs.jmedchem.9b00123","article-title":"Pharmacokinetics-driven optimization of 4(3 H)-Pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension","volume":"62","author":"Wang","year":"2019","journal-title":"J Med Chem"},{"key":"2025080406265937600_ref17","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.2147\/DDDT.S308610","article-title":"A phase I study to evaluate the safety, tolerability, and pharmacokinetics of TPN171H, a novel phosphodiesterase type 5 inhibitor, in healthy subjects","volume":"15","author":"Qian","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"2025080406265937600_ref18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/s0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"issue":"2","key":"2025080406265937600_ref19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/17425255.2017.1244265","article-title":"Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors","volume":"13","author":"Hong","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"2025080406265937600_ref20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/andr.12683","article-title":"The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue","volume":"7","author":"Zucchi","year":"2019","journal-title":"Andrology"},{"issue":"4","key":"2025080406265937600_ref21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0090-4295(00)00688-9","article-title":"Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 study group","volume":"56","author":"Tan","year":"2000","journal-title":"Urology"},{"issue":"4","key":"2025080406265937600_ref22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.ijir.3900685","article-title":"ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan","volume":"13","author":"Chen","year":"2001","journal-title":"Int J Impot Res"},{"issue":"7","key":"2025080406265937600_ref23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1442-2042.2004.00833.x","article-title":"Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan","volume":"11","author":"Nagao","year":"2004","journal-title":"Int J Urol"},{"issue":"3","key":"2025080406265937600_ref24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1743-6109.2007.00468.x","article-title":"On behalf of the Vardenafil study group null. The efficacy and safety of vardenafil in east Asian men with erectile dysfunction","volume":"4","author":"Chen","year":"2007","journal-title":"J Sex Med"},{"issue":"4 Part 1","key":"2025080406265937600_ref25","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J Urol"},{"issue":"6","key":"2025080406265937600_ref26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1442-2042.2006.01393.x","article-title":"Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in south-east Asian men","volume":"13","author":"Guo","year":"2006","journal-title":"Int J Urol"},{"issue":"2","key":"2025080406265937600_ref27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1743-6109.2004.04029.x","article-title":"Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study","volume":"1","author":"Chen","year":"2004","journal-title":"J Sex Med"},{"issue":"11","key":"2025080406265937600_ref28","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/j.1464-410X.2012.11095.x","article-title":"Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial","volume":"110","author":"Zhao","year":"2012","journal-title":"BJU Int"},{"issue":"9","key":"2025080406265937600_ref29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1464-410X.2008.08267.x","article-title":"Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies","volume":"103","author":"Mirone","year":"2009","journal-title":"BJU Int"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/8\/1430\/63694227\/qdaf109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/8\/1430\/63694227\/qdaf109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T10:27:05Z","timestamp":1754303225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/8\/1430\/8191422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf109","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,8]]}}}